Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma.

[1]  E. Erdal,et al.  Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells , 2016, Cancer science.

[2]  C. Porta,et al.  Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC). , 2016 .

[3]  Lin Qiu,et al.  Sorafenib enriches epithelial cell adhesion molecule–positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2‐AKT cascade , 2015, Hepatology.

[4]  J. Zucman‐Rossi,et al.  Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. , 2015, Gastroenterology.

[5]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[6]  H. Huynh,et al.  Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus , 2015, Molecular Cancer Therapeutics.

[7]  L. Roberts,et al.  Update on biomarkers of hepatocellular carcinoma. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[9]  D. Spaeth,et al.  Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. , 2015, Annals of Oncology.

[10]  J. Llovet,et al.  Advances in targeted therapies for hepatocellular carcinoma in the genomic era , 2015, Nature Reviews Clinical Oncology.

[11]  N. Shikata,et al.  Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma , 2015, Digestive Diseases and Sciences.

[12]  Hiromi Nakamura,et al.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.

[13]  W. Sung,et al.  Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification , 2014, Hepatology.

[14]  Nikhil Wagle,et al.  Response and acquired resistance to everolimus in anaplastic thyroid cancer. , 2014, The New England journal of medicine.

[15]  M. Kudo,et al.  Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. , 2014, JAMA.

[16]  Yitao Ding,et al.  Hepatic Stellate Cell Coculture Enables Sorafenib Resistance in Huh7 Cells through HGF/c-Met/Akt and Jak2/Stat3 Pathways , 2014, BioMed research international.

[17]  S. Imbeaud,et al.  Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas , 2014, Gut.

[18]  P. Schirmacher,et al.  Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. , 2014, Cancer discovery.

[19]  L. Schwartz,et al.  Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. , 2014, Hepatic oncology.

[20]  C. Sander,et al.  Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy , 2014, Clinical Cancer Research.

[21]  J. Llovet,et al.  Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design , 2014, Clinical Cancer Research.

[22]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[23]  Su Jin Lee,et al.  A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. , 2013, Anticancer research.

[24]  F. Eren,et al.  Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging. , 2013, Annals of hepatology.

[25]  J. Zucman‐Rossi,et al.  Corrigendum: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions , 2013, Nature Communications.

[26]  Lin Li,et al.  Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma , 2013, Genome research.

[27]  P. Zhan,et al.  Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis. , 2013, Hepatobiliary surgery and nutrition.

[28]  Y. Kodera,et al.  Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells. , 2013, Cancer letters.

[29]  Derek Y. Chiang,et al.  Identification of driver genes in hepatocellular carcinoma by exome sequencing , 2013, Hepatology.

[30]  Tohru Utsunomiya,et al.  FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma , 2013, Hepatology.

[31]  A. Zhu,et al.  Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[32]  D. Sahani,et al.  Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study , 2013, Clinical Cancer Research.

[33]  A. Gasbarrini,et al.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. , 2013, The Lancet. Oncology.

[34]  C. Sander,et al.  Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.

[35]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[36]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[37]  J. Bruix,et al.  Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma , 2012, Clinical Cancer Research.

[38]  M. Ryu,et al.  Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum , 2012, British Journal of Cancer.

[39]  D. Fingar,et al.  Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. , 2012, The Biochemical journal.

[40]  H. Ueno,et al.  Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma , 2013, International Journal of Clinical Oncology.

[41]  Jeffrey S. Morris,et al.  Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  B. Weigelt,et al.  PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs , 2011, Oncogene.

[43]  Takafumi Yoshida,et al.  The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. , 2010, Oncology reports.

[44]  Derek Y. Chiang,et al.  IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. , 2010, Journal of hepatology.

[45]  Derek Y. Chiang,et al.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.

[46]  G. Gores,et al.  Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis , 2009, British Journal of Cancer.

[47]  H. Lane,et al.  Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition , 2009, Molecular Cancer Therapeutics.

[48]  Jaume Bosch,et al.  Angiogenesis in liver disease. , 2009, Journal of hepatology.

[49]  Derek Y. Chiang,et al.  Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.

[50]  Derek Y. Chiang,et al.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.

[51]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[52]  S. Boyault,et al.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.

[53]  S. Thorgeirsson,et al.  Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. , 2006, The Journal of clinical investigation.

[54]  M. Torbenson,et al.  mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms , 2004, Clinical Cancer Research.

[55]  G. Thomas,et al.  Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. , 2001, Gastroenterology.